Sign In
Buy QGEN
$36.28
-0.670 (-1.81%)
At Close: Jun 22, 2026
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
04:12pm, Monday, 15'th Jun 2026
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use
12:21pm, Monday, 15'th Jun 2026
QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
01:30am, Monday, 15'th Jun 2026
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosys
A Look at Qiagen NV (QGEN) After 4.2% Gain -- GF Value $52.66 vs Price $37.75
07:52pm, Tuesday, 09'th Jun 2026
On June 09, 2026, Qiagen NV (QGEN) shares rose 4.2% today, bringing the current price to $37.75. The stock has experienced a 52-week range, hitting a high of $5
Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue?
12:35pm, Friday, 05'th Jun 2026
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
10:00am, Thursday, 04'th Jun 2026
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).
Qiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
03:12pm, Wednesday, 03'rd Jun 2026
Qiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
05:41pm, Tuesday, 02'nd Jun 2026
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE: QGEN). Such investors are advised to
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
10:20am, Friday, 29'th May 2026
QIAGEN cuts its 2026 growth outlook after a Q1 miss, but margins, cash flow and a debt-free balance sheet could steady the narrative.
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
04:05pm, Thursday, 28'th May 2026
VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-o
QIAGEN Business Breakdown and Growth Drivers for 2026
11:01am, Thursday, 28'th May 2026
QGEN targets steadier growth through 2027, leaning on new launches, Connect automation and QIAstat-Dx menu expansion amid choppy demand.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
10:05am, Thursday, 28'th May 2026
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
05:35pm, Tuesday, 26'th May 2026
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE: QGEN). Such investors are advised to c
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
08:00pm, Thursday, 21'st May 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concernin
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
03:25pm, Thursday, 21'st May 2026
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).
